{"id":35607,"date":"2025-11-18T16:18:10","date_gmt":"2025-11-18T21:18:10","guid":{"rendered":"https:\/\/joinastudy.ca\/?p=35607"},"modified":"2025-12-09T12:53:05","modified_gmt":"2025-12-09T17:53:05","slug":"glp-1-agonists-frequently-asked-questions","status":"publish","type":"post","link":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-frequently-asked-questions\/","title":{"rendered":"GLP-1 Agonists: Frequently Asked Questions"},"content":{"rendered":"

Curious about the science behind today\u2019s most talked-about diabetes and weight-management treatments? Our new, four-part blog series on GLP-1 Agonists<\/strong> will break down everything you need to know \u2014 from how these drugs work, to their real-world results, side effects, and what\u2019s coming next in the pipeline. Today, we\u2019re taking a look at some of the most frequently asked questions about GLP-1s, and providing answers sourced from some of the most reputable online publications.<\/p>\n

Q: Which GLP-1 drug\/molecule causes the most weight loss?<\/h4>\n

A: Current evidence suggests tirzepatide<\/a> (Zepbound for obesity) from Eli Lilly<\/a> is among the most effective for weight loss, with higher average weight loss compared to many others. Semaglutide<\/a> (in its obesity dose, i.e. Wegovy) from Novo Nordisk<\/a> is also very effective. But individual results vary.<\/p>\n

Q: Can I use a GLP-1 drug for weight loss even if I don\u2019t have type 2 diabetes?<\/h4>\n

A: Yes \u2014 but only some are approved for that use. For example, Wegovy<\/a> (semaglutide at obesity-dose), Saxenda<\/a> (liraglutide higher dose) or Zepbound<\/a>. Others are used \u201coff-label\u201d by some clinicians, but off-label use means less trial data in that setting, and possibly more out-of-pocket cost.<\/p>\n

Q: What about oral GLP-1s? Are they as good?<\/h4>\n

A: There is an oral version of semaglutide, Rybelsus<\/a>, approved for T2DM. It is less potent (or at least less weight loss in many studies) compared to injectable GLP-1s at high obesity doses. Also, the oral drug has stricter administration requirements (e.g. empty stomach, water only, wait before food\/other meds) to ensure absorption.<\/p>\n

Q: What are typical side effects of taking GLP-1s & how can they be reduced?<\/h4>\n

A: Nausea, vomiting, diarrhea, or constipation are the most common side effects, especially at the start of dosing or during dose increases. Tactics to reduce them include: starting at low dose and titrating slowly; taking with small meals; adjusting diet (more bland \/ lower fat temporarily); staying hydrated; maybe dividing doses (depending on formulation). If side effects are severe or persistent, it would be advisable to discuss this with provider about dose adjustment or switching agent. See more from Mayo Clinic: Liraglutide Safety Profile<\/a>.<\/p>\n

Q: How long should I expect to continue treatment once initiated?<\/h4>\n

A: Often long-term (chronic) therapy is needed if the condition (e.g. obesity, diabetes) is chronic. Sometimes people might try a course, lose weight, then maintain on a lower dose or possibly discontinue under medical supervision, but weight usually rebounds if lifestyle changes or therapy is stopped. For T2DM, therapy is often ongoing. Long-term outcomes from the STEP trials: Semaglutide STEP Trials<\/a>.<\/p>\n

Q: Will insurance \/ public health cover these?<\/h4>\n

A: It depends heavily on where you live, the specific drug & indication, the healthcare system, and your insurance plan. Some cover diabetes indications more readily; obesity indications are often more restricted. Co-pays or out-of-pocket cost may be high. Savings programs exist, such as:<\/p>\n

\u2022 Wegovy Savings Program<\/a><\/p>\n

\u2022 Lilly Zepbound Support<\/a><\/p>\n

Q: Are there drug interactions or safety issues?<\/h4>\n

A: Yes. Because they slow gastric emptying, they may affect absorption of oral medications. Also, risk of hypoglycemia is increased if combined with other glucose-lowering agents (especially insulin or sulfonylureas). Watch for pancreatitis symptoms. Use caution in people with severe renal impairment or GI disorders. Pregnancy\/lactation status should also be considered. FDA GLP-1 safety communication: FDA GLP-1 Warnings<\/a>.<\/p>\n

Q: How soon will I see effects (on sugar, weight)?<\/h4>\n

A: Glucose improvements can often be seen within days to weeks. HbA1c reductions usually over 3 months. Weight loss tends to be gradual over months; more significant weight loss typically requires staying on the appropriate maintenance dose for many weeks (often 16\u201368 weeks or longer in the obesity trials). Clinical results summary: Semaglutide Clinical Data<\/a>.<\/p>\n

Q: Can I switch from one GLP-1 to another?<\/h4>\n

A: Yes, sometimes. If one is poorly tolerated or not achieving goals, switching may help. But need to consider dosing equivalency\/titration, the indication, and risk of side effects. This should be done under medical supervision.<\/p>\n

Q: What about newer drugs \/ what\u2019s coming?<\/h4>\n

A: There is a pipeline of next-generation agents: dual or triple agonists (e.g. GLP-1 + GIP, or GLP-1 + glucagon + GIP), with more potent weight loss effects and possibly better safety\/tolerability. Browse ongoing clinical trials: GLP-1 Clinical Trials<\/a>. More oral options are being developed, and many are still in various trial phases.<\/p>\n

Thanks for reading our final article in our series highlighting GLP-1 agonists! If you enjoyed this article and haven’t yet checked out the rest of the series, you can click the following link to find all of our original content on this subject: https:\/\/joinastudy.ca\/canadian-health-blog\/<\/a><\/p>\n

\u00a0<\/span><\/p>\n

Sources<\/span><\/b>\u00a0<\/span><\/p>\n

https:\/\/my.clevelandclinic.org\/health\/treatments\/13901-glp-1-agonists<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medeffect-canada\/health-product-infowatch\/december-2024.html<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/pubmed.ncbi.nlm.nih.gov\/26371721\/<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.endocrinologyadvisor.com\/ddi\/glp-1-agonists\/<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/hopkinsdiabetesinfo.org\/medications-for-type-2-diabetes-glp-1-agonists\/<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551568\/<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/books\/n\/rc72848269830370\/<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/drug-shortages\/information-consumers\/supply-notices\/ozempic.html<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.practicenursing.com\/content\/clinical\/glp-1-receptor-agonists-and-their-role-in-managing-type-2-diabetes<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.drugs.com\/medical-answers\/glp-1-drug-best-weight-loss-3579236\/<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.primetherapeutics.com\/en\/glp-1-pipeline-update-november-2024<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/drug-shortages\/information-consumers\/supply-notices\/ozempic.html\/1000.html<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.avalanchept.com\/post\/comprehensive-list-of-fda-approved-glp-1-receptor-agonists-as-of-mid-2025<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.powerpak.com\/course\/content\/118150<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.powerpak.com\/course\/content\/114864<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.primetherapeutics.com\/glp-1-pipeline-update-february-2025<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/primetherapeutics.com\/glp-1-pipeline-update-may-2025<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/primetherapeutics.com\/glp-1-pipeline-november-2024<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.primetherapeutics.com\/glp-1-pipeline-update-november-2024<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/www.beckershospitalreview.com\/glp-1s\/glp-1-drug-approvals-a-breakdown.html<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/acgng.org\/most-popular-glp-1-medications\/<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

https:\/\/sanemd.com\/glp-1-medications\/glp-1-medications-list-benefits-uses-side-effects\/<\/span><\/b><\/a>\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Curious about the science behind today\u2019s most talked-about diabetes and weight-management treatments? Our new, four-part blog series on GLP-1 Agonists will break down everything you need to know \u2014 from how these drugs work, to their real-world results, side effects, and what\u2019s coming next in the pipeline. Today, we\u2019re taking a look at some of<\/p>\n","protected":false},"author":964,"featured_media":28702,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[603,605,487,513],"tags":[],"class_list":["post-35607","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-obesity-weight-loss","category-diabetes","category-drug-development","category-health-and-wellness","category-603","category-605","category-487","category-513","description-off"],"acf":[],"yoast_head":"\nGLP-1s: The Future of Diabetes Treatment Explained - JoinAStudy.ca<\/title>\n<meta name=\"description\" content=\"Dive into our series on GLP-1s to understand their role in diabetes care and weight management, along with expert insights.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-frequently-asked-questions\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GLP-1 Agonists: Frequently Asked Questions\" \/>\n<meta property=\"og:description\" content=\"Dive into our series on GLP-1s to understand their role in diabetes care and weight management, along with expert insights.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-frequently-asked-questions\/\" \/>\n<meta property=\"og:site_name\" content=\"JoinAStudy.ca\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/joinastudy.ca\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-18T21:18:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-09T17:53:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/joinastudy.ca\/wp-content\/uploads\/t2dm-obesity.png\" \/>\n\t<meta property=\"og:image:width\" content=\"934\" \/>\n\t<meta property=\"og:image:height\" content=\"655\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"JoinAStudy Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@JoinAStudy_ca\" \/>\n<meta name=\"twitter:site\" content=\"@JoinAStudy_ca\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"JoinAStudy Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-frequently-asked-questions\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-frequently-asked-questions\\\/\"},\"author\":{\"name\":\"JoinAStudy Team\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#\\\/schema\\\/person\\\/da824a10716e724d72676ec94d865d71\"},\"headline\":\"GLP-1 Agonists: Frequently Asked Questions\",\"datePublished\":\"2025-11-18T21:18:10+00:00\",\"dateModified\":\"2025-12-09T17:53:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-frequently-asked-questions\\\/\"},\"wordCount\":953,\"publisher\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-frequently-asked-questions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/t2dm-obesity.png\",\"articleSection\":[\"Obesity & Weight Loss\",\"Diabetes\",\"Drug Development\",\"Health and Wellness\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-frequently-asked-questions\\\/\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-frequently-asked-questions\\\/\",\"name\":\"GLP-1s: The Future of Diabetes Treatment Explained - JoinAStudy.ca\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-frequently-asked-questions\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-frequently-asked-questions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/t2dm-obesity.png\",\"datePublished\":\"2025-11-18T21:18:10+00:00\",\"dateModified\":\"2025-12-09T17:53:05+00:00\",\"description\":\"Dive into our series on GLP-1s to understand their role in diabetes care and weight management, along with expert insights.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-frequently-asked-questions\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-frequently-asked-questions\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-frequently-asked-questions\\\/#primaryimage\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/t2dm-obesity.png\",\"contentUrl\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/t2dm-obesity.png\",\"width\":934,\"height\":655,\"caption\":\"obesity, GLP-1s, osteoarthritis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/glp-1-agonists-frequently-asked-questions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GLP-1 Agonists: Frequently Asked Questions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/\",\"name\":\"JoinAStudy.ca\",\"description\":\"JoinAStudy.ca - Help create a healthier future\",\"publisher\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#organization\",\"name\":\"JoinAStudy.ca\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/JoinaStudy-Logo-Mobile-e1520526932796.png\",\"contentUrl\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/JoinaStudy-Logo-Mobile-e1520526932796.png\",\"width\":118,\"height\":65,\"caption\":\"JoinAStudy.ca\"},\"image\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/joinastudy.ca\",\"https:\\\/\\\/x.com\\\/JoinAStudy_ca\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UC_ed0XmzH5ImSNOEJcdXKqg\"],\"publishingPrinciples\":\"https:\\\/\\\/joinastudy.ca\\\/why-join-a-study\\\/\",\"ownershipFundingInfo\":\"https:\\\/\\\/joinastudy.ca\\\/information-disclaimer\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#\\\/schema\\\/person\\\/da824a10716e724d72676ec94d865d71\",\"name\":\"JoinAStudy Team\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/author\\\/grant\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GLP-1s: The Future of Diabetes Treatment Explained - JoinAStudy.ca","description":"Dive into our series on GLP-1s to understand their role in diabetes care and weight management, along with expert insights.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-frequently-asked-questions\/","og_locale":"fr_FR","og_type":"article","og_title":"GLP-1 Agonists: Frequently Asked Questions","og_description":"Dive into our series on GLP-1s to understand their role in diabetes care and weight management, along with expert insights.","og_url":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-frequently-asked-questions\/","og_site_name":"JoinAStudy.ca","article_publisher":"https:\/\/www.facebook.com\/joinastudy.ca","article_published_time":"2025-11-18T21:18:10+00:00","article_modified_time":"2025-12-09T17:53:05+00:00","og_image":[{"width":934,"height":655,"url":"https:\/\/joinastudy.ca\/wp-content\/uploads\/t2dm-obesity.png","type":"image\/png"}],"author":"JoinAStudy Team","twitter_card":"summary_large_image","twitter_creator":"@JoinAStudy_ca","twitter_site":"@JoinAStudy_ca","twitter_misc":{"\u00c9crit par":"JoinAStudy Team","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-frequently-asked-questions\/#article","isPartOf":{"@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-frequently-asked-questions\/"},"author":{"name":"JoinAStudy Team","@id":"https:\/\/joinastudy.ca\/fr\/#\/schema\/person\/da824a10716e724d72676ec94d865d71"},"headline":"GLP-1 Agonists: Frequently Asked Questions","datePublished":"2025-11-18T21:18:10+00:00","dateModified":"2025-12-09T17:53:05+00:00","mainEntityOfPage":{"@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-frequently-asked-questions\/"},"wordCount":953,"publisher":{"@id":"https:\/\/joinastudy.ca\/fr\/#organization"},"image":{"@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-frequently-asked-questions\/#primaryimage"},"thumbnailUrl":"https:\/\/joinastudy.ca\/wp-content\/uploads\/t2dm-obesity.png","articleSection":["Obesity & Weight Loss","Diabetes","Drug Development","Health and Wellness"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-frequently-asked-questions\/","url":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-frequently-asked-questions\/","name":"GLP-1s: The Future of Diabetes Treatment Explained - JoinAStudy.ca","isPartOf":{"@id":"https:\/\/joinastudy.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-frequently-asked-questions\/#primaryimage"},"image":{"@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-frequently-asked-questions\/#primaryimage"},"thumbnailUrl":"https:\/\/joinastudy.ca\/wp-content\/uploads\/t2dm-obesity.png","datePublished":"2025-11-18T21:18:10+00:00","dateModified":"2025-12-09T17:53:05+00:00","description":"Dive into our series on GLP-1s to understand their role in diabetes care and weight management, along with expert insights.","breadcrumb":{"@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-frequently-asked-questions\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/joinastudy.ca\/fr\/glp-1-agonists-frequently-asked-questions\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-frequently-asked-questions\/#primaryimage","url":"https:\/\/joinastudy.ca\/wp-content\/uploads\/t2dm-obesity.png","contentUrl":"https:\/\/joinastudy.ca\/wp-content\/uploads\/t2dm-obesity.png","width":934,"height":655,"caption":"obesity, GLP-1s, osteoarthritis"},{"@type":"BreadcrumbList","@id":"https:\/\/joinastudy.ca\/fr\/glp-1-agonists-frequently-asked-questions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/joinastudy.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"GLP-1 Agonists: Frequently Asked Questions"}]},{"@type":"WebSite","@id":"https:\/\/joinastudy.ca\/fr\/#website","url":"https:\/\/joinastudy.ca\/fr\/","name":"JoinAStudy.ca","description":"JoinAStudy.ca - Help create a healthier future","publisher":{"@id":"https:\/\/joinastudy.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/joinastudy.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/joinastudy.ca\/fr\/#organization","name":"JoinAStudy.ca","url":"https:\/\/joinastudy.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/joinastudy.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/joinastudy.ca\/wp-content\/uploads\/JoinaStudy-Logo-Mobile-e1520526932796.png","contentUrl":"https:\/\/joinastudy.ca\/wp-content\/uploads\/JoinaStudy-Logo-Mobile-e1520526932796.png","width":118,"height":65,"caption":"JoinAStudy.ca"},"image":{"@id":"https:\/\/joinastudy.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/joinastudy.ca","https:\/\/x.com\/JoinAStudy_ca","https:\/\/www.youtube.com\/channel\/UC_ed0XmzH5ImSNOEJcdXKqg"],"publishingPrinciples":"https:\/\/joinastudy.ca\/why-join-a-study\/","ownershipFundingInfo":"https:\/\/joinastudy.ca\/information-disclaimer\/"},{"@type":"Person","@id":"https:\/\/joinastudy.ca\/fr\/#\/schema\/person\/da824a10716e724d72676ec94d865d71","name":"JoinAStudy Team","url":"https:\/\/joinastudy.ca\/fr\/author\/grant\/"}]}},"_links":{"self":[{"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/posts\/35607","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/users\/964"}],"replies":[{"embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/comments?post=35607"}],"version-history":[{"count":9,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/posts\/35607\/revisions"}],"predecessor-version":[{"id":35654,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/posts\/35607\/revisions\/35654"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/media\/28702"}],"wp:attachment":[{"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/media?parent=35607"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/categories?post=35607"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/tags?post=35607"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}